Evidence map›Paper›PMID 42731874›Full record

ArticleJournal for immunotherapy of cancer2026

Epigenetic plus cytokine therapy induces stem-like CD8

Christine Mall Minnar, Masaya Miyamoto, Asma Sarah Khelifa, Grace Lui, Katherine E Lothstein, Ainara Meler, Maria Del Mar Maldonado, Duane H Hamilton, Lisa K Poppe, Nicholas Roller and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Christine Mall MinnarCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0001-7497-9459
Masaya Miyamoto *Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Asma Sarah Khelifa *Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-2608-0673
Grace LuiCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Katherine E LothsteinCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Ainara MelerCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-0026-7325
Maria Del Mar MaldonadoCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0001-6847-2707
Duane H HamiltonCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-9730-8209
Lisa K PoppeCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-9506-372X
Nicholas RollerCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Kenneth CanubasCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
George ZakiFrederick National Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.ORCID http://orcid.org/0000-0002-2740-3307
Wiem LassouedCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0009-0004-5742-6982
Alexei LobanovCCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Darryl NousomeCCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Richard FinneyCCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Margaret CamCCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Patrick Soon-ShiongImmunityBio, Culver City, California, USA.
James L GulleyCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-6569-2912
Jeffrey SchlomCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA schlomj@mail.nih.gov.ORCID http://orcid.org/0000-0001-7932-4072
Sofia R GameiroCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-2392-8122

Funding

Strategies for Cancer Vaccine Development: Preclinical StudiesZIABC010944 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHLOM, JEFFREY · 2009 to 2025
$26.6M
Intramural NIH HHS ZIA BC010944
6 · The paper itself

Abstract

backgroundCheckpoint blockade (CPB) has limited efficacy in patients with colorectal cancer (CRC), warranting improved therapeutic strategies capable of remodeling the tumor microenvironment. Stem-like TCF1

methodsWe evaluated the combination of αPD-1, the class I histone deacetylase inhibitor entinostat, and the IL-15 superagonist N-803 in CPB-resistant murine CRC and breast cancer models with varying antigen presentation deficiencies. Proteomic, transcriptomic, spatial, and functional analyses were completed to identify treatment-specific immune remodeling. Translational relevance was assessed using publicly available CPB-treated cancer genomic datasets and functional assays with patient-derived peripheral blood mononuclear cells (PBMCs).

resultsTriple therapy increased stem-like TCF1

conclusionsTreatment with entinostat, N-803, and αPD-1 boosts anti-tumor intratumoral immune niches comprising TCF1

Indexed as

CD8-Positive T-LymphocytesColorectal NeoplasmsCytokinesDrug Resistance, NeoplasmImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAnimalsBenzamidesEpigenesis, GeneticFemaleHumansMicePyridinesTumor MicroenvironmentBenzamidesCytokinesentinostatImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPyridinesCombination therapyCytokineImmune Checkpoint InhibitorImmunotherapyTumor microenvironment - TME

Identifiers

PMID42731874
PMCPMC13583839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.